Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
GlaxoSmithKline
Pharmacyclics LLC.
Fate Therapeutics
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)